SAB BIOTHERAPEUTICS, INC. Gain (Loss) on Extinguishment of Debt
SAB BIOTHERAPEUTICS, INC. (SABS) reported Gain (Loss) on Extinguishment of Debt of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-04-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2023-04-28
- SAB BIOTHERAPEUTICS, INC. gain (loss) on extinguishment of debt for the quarter ending 2021-12-31 was $0.00.
- SAB BIOTHERAPEUTICS, INC. gain (loss) on extinguishment of debt for the quarter ending 2021-09-30 was $0.00.
- SAB BIOTHERAPEUTICS, INC. gain (loss) on extinguishment of debt for the quarter ending 2021-06-30 was $0.00.
- SAB BIOTHERAPEUTICS, INC. gain (loss) on extinguishment of debt for the quarter ending 2021-03-31 was $665.60K.
- SAB BIOTHERAPEUTICS, INC. gain (loss) on extinguishment of debt for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- SAB BIOTHERAPEUTICS, INC. gain (loss) on extinguishment of debt for fiscal 2021 was $665.60K.
- SAB BIOTHERAPEUTICS, INC. gain (loss) on extinguishment of debt for fiscal 2020 was $0.00.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-04-14 | |||
| 2021-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-04-28 | $0.00 derived: sum of 2 quarters · filed 2023-04-28 | $0.00 derived: sum of 3 quarters · filed 2023-04-28 | $665.60K 10-K/A · filed 2023-04-28 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | $665.60K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $665.60K 10-Q · filed 2022-08-10 | ||
| 2021-03-31 | $665.60K 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $0.00 10-K/A · filed 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |